The BDI of the beholder

Journal of Psychopharmacology

Volumn 16, Issue 1, 2002, Pages 103-

  Cole, J C ^a   Sumnall, H R ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; PLACEBO;

BECK DEPRESSION INVENTORY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; HUMAN; LETTER; MALE; MENTAL DISEASE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TREATMENT OUTCOME;

EID: 0036211762     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/026988110201600109     Document Type: Letter

References (7)

1. An inventory for measuring depression
2. Mood and cognitive effects of 3, 4-methylenedioxymethamphetamine (MDMA 'ecstacy'): Week-end 'high' followed by mid-week low
3. Serotonergic function after (±)3,4-methylene-dioxymethamphetamine ('ecstasy') in humans
4. Long-lasting effects of (±)3,4-methylenedioxymethamphetamine (Ecstasy) on serotonin system function in humans
5. Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depression
6. Serotonergic involvement in the psychosocial dimension of personality
7. Cognitive performance and serotonergic function in users of ecstasy